Sankala Group
RCKT icon

Sankala Group’s Rocket Pharmaceuticals RCKT Stock Holding History

Sankala Group’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.19K Hold
828
– – ﹤0.01% 491
2026
Q2 		$2.74K Hold
828
– – ﹤0.01% 493
2026
Q1 		$3.21K Hold
828
– – ﹤0.01% 465
2025
Q4 		$4.15K Buy
+828
New +$2.84K ﹤0.01% 461

Other funds holding RCKT

Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Monaco Asset Management
Monaco Asset Management Monaco $818M AUM 32.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $468B AUM 17.69% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Privium Fund Management
Privium Fund Management Amsterdam, Netherlands $516M AUM 18.66% 1-Year Est. Return
Hennion & Walsh Asset Management
Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.8B AUM 26.98% 1-Year Est. Return

Sankala Group's RCKT Position: Q3 2026 in Review

Sankala Group held its Rocket Pharmaceuticals (RCKT) position steady in Q3 2026 at 828 shares worth $2.19K. The position accounts for ﹤0.01% of the portfolio, ranked #491.

Sankala Group first reported a position in RCKT in Q4 2025 and has held it in 4 quarters since. The position peaked at $4.15K in Q4 2025. 59 funds tracked by Wall St. Rank hold RCKT as of Q3 2026.

  • Sankala Group held 828 shares of Rocket Pharmaceuticals worth $2.19K as of Q3 2026.
  • Sankala Group left its Rocket Pharmaceuticals share count unchanged in Q3 2026.
  • Rocket Pharmaceuticals made up ﹤0.01% of Sankala Group's portfolio in Q3 2026, its #491 holding.
  • Sankala Group first reported a position in Rocket Pharmaceuticals in Q4 2025 and has held it in 4 quarters since.
  • Sankala Group's Rocket Pharmaceuticals position peaked at $4.15K in Q4 2025.
  • 59 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2026.

Based on Sankala Group's 13F filing for Q3 2026, filed 9 Nov 2026.